摘要
目的将介入治疗、三维适形放疗和氩氦靶向冷冻消融治疗(氩氦刀治疗)三种方法结合比较,探讨不适合手术的原发性肝癌患者的较好治疗方案。方法将符合入选的116例原发性肝癌患者分为单纯介入组(A组)、介入+三维适形放疗(3DCRT)组(B组)和介入+氩氦刀组(C组),比较三组的生存情况。结果 (1)A组、B组和C组1年生存率分别是14.98%、64%、85.71%;2年生存率分别是11.24%、32%、64.29%;3年生存率分别是0、0、32.14%。(2)三组间生存函数曲线差异有显著性(P<0.05),C组的生存曲线较A组和B组好。结论介入+氩氦刀治疗能延长患者的生存时间,是不适合手术的原发性肝癌患者的较好治疗方案。
Objective To find out a better therapy for unresectable HCC on the basis of the survival time by using three methods compared which were interventional therapy(IVT),three-dimensional conformal radiotherapy(3D-CRT),and targeted argon-helium cryoablation therapy(AHC).Methods Total of 116 patients with unresectable HCC were divided into three groups which were IVT group(A group),the IVT and 3D-CRT group(B group) and the IVT and AHC group(C group).Results The survival rates for 1 year in A,B and C group were 14.98%,64.00%,85.71%,respectively.The corresponding survival rates for 2 year were 11.24%,32%,64.29%,respectively.The corresponding survival rates for 3 year were 0,0,32.14%,respectively.2.There were significantly different of survival functions in three groups(P0.05).The survival curves of C group were better than that of A group and B group.Conclusion The IVT and ACH are a suitable therapy with unresectable HCC because of increased survival time of the patients.
出处
《贵州医药》
CAS
2010年第8期687-690,共4页
Guizhou Medical Journal
关键词
原发性肝癌
肝动脉灌注化疗
肝动脉化疗栓塞
三维适形放射治疗
氩氦靶向冷冻消融治疗
生存时间
Hepatocellular carcinoma(HCC) Transcatheter arterial infusion transcatheter arterial chemoembolization Three-dimensional conformal radiotherapy targeted argon-helium cryoablation therapy Survival time